Evidence map›Paper›PMID 36617519›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2023

The worldwide costs of dementia in 2019.

Anders Wimo, Katrin Seeher, Rodrigo Cataldi, Eva Cyhlarova, Joseph L Dielemann, Oskar Frisell, Maëlenn Guerchet, Linus Jönsson, Angeladine Kenne Malaha, Emma Nichols and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 289 papers, 18 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
289citing papers in PubMed, 18 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

289 citing papers in PubMed, 18 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Trial
  20. Trial

229 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Anders WimoDepartment of Neurobiology, Care Sciences and Society, Karolinska Institute, Solna, Sweden.
Katrin SeeherWorld Health Organization, Geneva, Switzerland.
Rodrigo CataldiWorld Health Organization, Geneva, Switzerland.
Eva CyhlarovaCare Policy and Evaluation Centre, London School of Economics and Political Science, London, UK.
Joseph L DielemannInstitute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, USA.
Oskar FrisellLinköping University, Linköping, Sweden.
Maëlenn GuerchetInserm U1094, IRD U270, Univ. Limoges, CHU Limoges, EpiMaCT - Epidemiology of Chronic Diseases in Tropical Zone, Institute of Epidemiology and Tropical Neurology, OmegaHealth, Limoges, France.
Linus JönssonDepartment of Neurobiology, Care Sciences and Society, Karolinska Institute, Solna, Sweden.
Angeladine Kenne MalahaInserm U1094, IRD U270, Univ. Limoges, CHU Limoges, EpiMaCT - Epidemiology of Chronic Diseases in Tropical Zone, Institute of Epidemiology and Tropical Neurology, OmegaHealth, Limoges, France.
Emma NicholsInstitute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, USA.
Paola PedrozaInstitute for Health Metrics and Evaluation, University of Washington, Seattle, Washington, USA.
Martin PrinceKing's College London, London, UK.
Martin KnappCare Policy and Evaluation Centre, London School of Economics and Political Science, London, UK.
Tarun DuaWorld Health Organization, Geneva, Switzerland.

Funding

EPIDEMIOLOGY AND BIOSTATISTICS OF AGINGT32AG000247 · NIA · JOHNS HOPKINS UNIVERSITY · PI Karen J. Bandeen-Roche · 1996 to 2026
$13.2M
NIA NIH HHS T32 AG000247World Health Organization 001
6 · The paper itself

Abstract

introductionDementia is a leading cause of death and disability globally. Estimating total societal costs demonstrates the wide impact of dementia and its main direct and indirect economic components.

methodsWe constructed a global cost model for dementia, presenting costs as cumulated global and regional costs.

resultsIn 2019, the annual global societal costs of dementia were estimated at US $1313.4 billion for 55.2 million people with dementia, corresponding to US $23,796 per person with dementia. Of the total, US $213.2 billion (16%) were direct medical costs, US $448.7 billion (34%) direct social sector costs (including long-term care), and US $651.4 billion (50%) costs of informal care. DISCUSSION: The huge costs of dementia worldwide place enormous strains on care systems and families alike. Although most people with dementia live in low- and middle-income countries, highest total and per-person costs are seen in high-income countries. HIGHLIGHTS: Global economic costs of dementia were estimated to reach US $1313.4 in 2019. Sixty-one percent of people with dementia live in low-and middle-income countries, whereas 74% of the costs occur in high-income countries. The impact of informal care accounts for about 50% of the global costs. The development of a long-term care infrastructure is a great challenge for low-and middle-income countries. There is a great need for more cost studies, particularly in low- and middle-income countries. Discussions of a framework for global cost comparisons are needed.

Indexed as

DementiaCost of IllnessHealth Care CostsHumansAlzheimer´s diseasecostcost-of-illness studydementiaeconomicsinformal care

Identifiers

PMID36617519
PMCPMC10842637

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.